Wed Mar 23, 2016 10:21am EDT
Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments - Research and Markets
Research and Markets
(http://www.researchandmarkets.com/research/3dtrtp/parkinsons)
has announced the addition of the "Parkinson's
Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts
Towards Disease-Modifying Therapies, while Short Term Growth Driven by
Long-Acting Symptomatic Treatments" report to their offering.
The global Parkinson's Disease (PD) prevalence was estimated at
16.1 million in 2011, and after Alzheimer's disease it is the second most
common neurodegenerative disease worldwide.
Parkinson's Disease (PD) is a progressive disease and, although
not fatal, it can develop severe symptoms and complications that significantly
impact upon the patient's quality of life. Symptoms for each stage can be
categorized into early, moderate and advanced stages. Major motor symptoms of
Parkinson's Disease (PD) include tremors and difficulty walking. Parkinson's
Disease (PD) also gives rise to non-motor symptoms, such as dementia,
depression, hallucinations and loss of taste and smell.
There are several different drug classes available to relieve
Parkinson's Disease (PD) symptoms. The aim is for treatments to increase
dopamine levels, which is substantially diminished in brains affected by
Parkinson's Disease (PD). The most common therapies include levodopa, dopamine
agonists and Monoamine Oxidase-B (MAO-B) inhibitors, with the choice of
therapies dependent on patient symptoms and lifestyle. As the disease develops,
the medication will need to be taken more strictly, due to the effect of drugs
wearing off (known as off- time), which causes symptoms to return before the
next dose.
With the current marketed drugs focusing primarily on
symptomatic relief, Parkinson's Disease (PD) remains incurable, with a huge
unmet need for disease-modifying therapies. However, due to the lack of clearly
established clinical trial methodologies, replication of the benefits
demonstrated by neuroprotective agents in the laboratory to human trials has
proved challenging. More importantly, due to an incomplete understanding of the
underlying mechanisms that cause the disease, a viable therapeutic target to
halt or slow disease progression is currently not in scope, which limits the
effectiveness of current product development programs.
Key Topics Covered:
1 Tables & Figures
2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Epidemiology
2.6 Disease Stages
2.7 Co-morbidities and Complications
2.8 Diagnosis
2.9 Assessment of Disease Severity
2.10 Treatment
2.11 Treatment Algorithm
3 Marketed Products
3.1 Overview
3.2 Comparative Efficacy and Safety
4 Pipeline for Parkinson's Disease
4.1 Overview
4.2 Pipeline Distribution by Mechanism of Action/Molecular
Target
4.3 Clinical Trials
4.4 Promising Pipeline Molecules
4.5 Heatmaps of Safety and Efficacy for Parkinson's Disease Pipeline
and Marketed Products
4.6 Pipeline Product Heat Map and Product Competitiveness
Framework
5 Market Forecast to 2021
5.1 Geographical Markets
5.2 Drivers and Barriers
6 Strategic Consolidations
6.1 Major Co-Development Deals
6.2 Major Licensing Deals
7 Appendix
Companies Mentioned
- 23andMe
- Catalent Pharma Solutions
- Cephalon
- Dainippon Sumitomo Pharma
- Dexcel Pharma
- Genentech
- Hitachi
- MJFF
- MedGenesis Therapeutix
- Mesoblast
- Neuropore Therapies
- Pfizer
- Prothena
- Sellas Life Sciences
- TechnoPhage
- UbiQ
- Ubiquigent
For more information visit http://www.researchandmarkets.com/research/3dtrtp/parkinsons
View source version on businesswire.com: http://www.businesswire.com/news/home/20160323005979/en/
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector:
Pharmaceuticals
http://health.einnews.com/article/317936665/inkvMqaK-edd5Nh3
No comments:
Post a Comment